Early low-dose steroids for adults admitted to hospital with influenza-like illness during a pandemic: a randomised placebo controlled trial

The ASAP Trial: Improving patient treatment in hospitals during a respiratory viral pandemic

The ASAP (Adjuvant Steroids in Adults with Pandemic Influenza) trial is a scientific study looking at improving the treatment of patients that are admitted to hospital with “flu” during a pandemic.

What is a flu pandemic?

Influenza pandemics are natural phenomena that have occurred from time to time for centuries – including three times during the 20th century. They result when a new flu virus which is different to recently circulating strains emerges meaning that very few people have any protection against the virus. The virus can therefore spread easily and can cause more serious illness. Unlike ‘ordinary flu’ that occurs every winter in the UK, pandemic flu can occur at any time of the year and seasonal flu injections do not protect people against pandemic flu.

During a pandemic it is expected that many millions of people around the world will become infected, up to around 50% become ill with symptoms and a variable proportion die from the disease itself or from complications such as pneumonia. The worst pandemic of the last century occurred over 1918 to 1919. Often referred to as “Spanish flu”, it killed between 20 to 40 million people worldwide.


Where will the trial take place?

The ASAP Flu Trial will take place in several hospitals throughout the United Kingdom. Adults who are admitted to hospital with flu-like symptoms during a flu pandemic will be given the opportunity to take part in the trial.

It is planned for 2200 patients to take part in the trial and we will be looking to see how much the treatment has helped patients with flu and hopefully improve the treatment for pandemic flu patients in the future.

The ASAP trial is funded by the National Institute for Health Research (NIHR), sponsored by Nottingham University Hospitals NHS Trust and is being co-ordinated by the Nottingham Clinical Trials Unit.

Please note that this trial has not yet started. We are currently in the process of setting up the trial so that patients can participate in the trial from the start of the next flu pandemic. This website will be updated continually.

The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HTA programme, NIHR, NHS or the Department of Health.


This project was funded by the National Institute for Health Research Health Technology Assessment Programme (project number 12/127/10). Trial Identifier: ISRCTN72331452. EudraCT Number: 2013-001051-12.